Leptotrichia wadei Bacteremia: Clinical Overview
Leptotrichia wadei bacteremia is a rare opportunistic infection occurring primarily in immunocompromised patients, particularly those with neutropenia, hematologic malignancies, or mucosal barrier disruption, and should be treated with beta-lactam antibiotics (cefepime or carbapenems) for 4-6 weeks with prompt source control.
Clinical Features
Patient Population at Risk
L. wadei bacteremia occurs almost exclusively in specific high-risk populations 1, 2, 3, 4:
- Neutropenic patients (most common): Particularly those with acute myeloid leukemia or other hematologic malignancies receiving chemotherapy
- Immunosuppressed patients: Those on high-dose immunosuppressants or corticosteroids
- Patients with mucosal disruption: Oral mucositis, esophagitis, or gastrointestinal ulceration
Clinical Presentation
The organism typically presents with 1, 2, 3:
- Fever and sepsis: Often developing during neutropenic episodes
- Minimal localizing symptoms: Many patients have few symptoms beyond fever
- Rapid progression possible: Can lead to septic shock in severely immunocompromised hosts
- Source: Translocation from oral cavity, gastrointestinal tract, or female genital tract through disrupted mucosal barriers
Key Risk Factors
- Neutropenia (absolute neutrophil count <500 cells/mm³)
- Oral mucositis or ulceration
- Recent chemotherapy
- Central venous catheters 2
- Prior antibiotic exposure (particularly fluoroquinolones and vancomycin, to which Leptotrichia is resistant) 5
Diagnosis
Microbiologic Identification
L. wadei is a fastidious, facultative anaerobic, fusiform, pencil-shaped gram-negative rod 1, 2, 4:
- Gram stain: Large fusiform, gram-negative or gram-variable bacilli 6
- Culture: Slow-growing, may require extended incubation (48-72 hours)
- Biochemical testing: Often unsuccessful for species identification 6
- Definitive identification: Requires MALDI-TOF mass spectrometry (genus level) and 16S rRNA gene sequencing (species level) 1, 2, 6
Blood Culture Recommendations
Blood cultures should be obtained in all neutropenic or immunocompromised patients with fever, particularly those with:
- Oral mucositis or mucosal lesions
- Central venous catheters
- Recent chemotherapy exposure
- Signs of sepsis or hemodynamic instability
Following guideline principles for bacteremia evaluation 7, repeat blood cultures daily until sterile to assess treatment adequacy.
Treatment
Antibiotic Selection
Beta-lactam antibiotics are the treatment of choice 1, 2, 3:
- First-line empiric therapy: Cefepime (covers both gram-negatives and Leptotrichia)
- Alternative agents: Carbapenems (meropenem, imipenem-cilastatin)
- Avoid: Fluoroquinolones and vancomycin (intrinsic resistance) 5
Treatment Duration
Following endocarditis and bacteremia guidelines 7:
- Standard bacteremia: 4-6 weeks of IV therapy
- Complicated cases (persistent bacteremia >72 hours, metastatic foci): Minimum 6 weeks
- With endocarditis (rare but reported 4): 6 weeks minimum
Source Control
Immediate source control is critical 7, 8:
- Remove central venous catheters if present, especially if bacteremia persists >72 hours despite appropriate antibiotics 8
- Address mucosal lesions: Supportive care for mucositis, consider granulocyte colony-stimulating factor if neutropenic
- Repeat blood cultures: Daily until negative to document clearance 7
Monitoring
- Daily blood cultures until sterile
- Clinical assessment for metastatic infection (rare but possible)
- Consider echocardiography (TEE preferred) if bacteremia persists >72 hours or new murmur develops 7
Prognosis
Mortality and Outcomes
- Generally favorable with appropriate antibiotic therapy 1, 2, 3
- Mortality risk factors:
- Delayed recognition and treatment
- Severe underlying immunosuppression
- Persistent neutropenia
- Development of septic shock
- Failure to achieve source control
Recovery Factors
Most patients recover fully when:
- Appropriate beta-lactam therapy initiated promptly
- Neutropenia resolves (with G-CSF support if needed)
- Mucosal barriers heal
- Central lines removed if infected
Clinical Pitfalls
Common diagnostic challenges:
- Misidentification: Biochemical testing fails; requires molecular methods 6
- Delayed recognition: Slow growth may delay identification by 48-72 hours
- Inappropriate empiric coverage: Standard neutropenic fever regimens with vancomycin + fluoroquinolone miss this organism 5
Treatment errors to avoid:
- Continuing vancomycin or fluoroquinolones (intrinsically resistant)
- Inadequate treatment duration (<4 weeks)
- Failure to remove infected central lines
- Not repeating blood cultures to document clearance